West Pharmaceutical Services Inc (WST)
OvervaluedFundamental
66
Price
$392.15
Market Cap
$27.69B
Part 1 · What the company is worth
Overview
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$3.33B
Trailing 12 months (through 6/30/2026)
Net Income
$565M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$469M
Total Equity
$3.18B
Total Liabilities
$1.09B
Current Ratio
2.82
Interest Coverage
151.20
Debt/EBITDA
0.42
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$260.35
Current Price
$392.15
Margin of Safety
-50.6%
Fair Value Range
$169.23 - $351.48
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
50.21
ROE
15.5%
P/B Ratio
9.23
P/FCF
63.17
Gross Margin
36.8%
ROIC
15.6%
Profitability Radar
Value Creation (Economic Moat)
ROIC
15.6%
WACC
10.7%
ROIC − WACC
+4.9 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (20)
- EPS shows upward trend
- EPS CAGR 6.05%
- Price CAGR 16.02%
- ROIC 15.6%
- Gross margin 36.8%
- Debt/equity ratio
- Operating margin 20.5%
- Positive free cash flow
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- Low reliance on intangibles
- ROE 18.5%
- Revenue growth 5Y 7.4%
- Earnings surprise, average 16.0%
- Earnings quality (operating cash flow / net income) 1.17
- Share dilution -1.3%
- Net margin trend 17.0% vs 16.5%
- Piotroski F-Score 7/9
Failed (6)
- P/FCF 63.17
- P/B ratio 9.23
- CapEx intensity
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG ratio 6.07
Unavailable (1)
- Dividend payout –
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Robert W. McMahon C.M.A. | Senior VP & CFO | 56 |
| Ms. Annette F. Favorite | Chief HR Officer & Senior VP | 60 |
| Mr. Shane A. Campbell | SVP & Chief Proprietary Segment Officer | 45 |
| Mr. Michel Lagarde | President, CEO & Director | 50 |
| Mr. Chad R. Winters | VP of Finance & Chief Accounting Officer | 46 |
| Dr. Devesh Mathur | Senior VP & CTO | - |
| Mr. John P. Sweeney C.F.A. | Vice President of Investor Relations | - |
| Mr. Norman D. Finch Jr. | Senior VP, General Counsel & Corporate Secretary | 60 |
| Ms. Michele Polinsky | Vice President of Global Communications | - |
| Mr. Rudy J. Poussot | Senior Vice President of Strategy & Corporate Development | 55 |
Audit Risk
10
Board Risk
4
Compensation Risk
5
Shareholder Rights Risk
4
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-17
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-23
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-07-23
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much WST moves, measured on its daily prices.
More volatile than 18% of the tracked stocks (90-day volatility).
- Volatility 30d
- 21.7%
- Volatility 90d
- 23.8%
- Beta vs S&P 500 (1y)
- 0.60Correlation 0.23
- Max drawdown (12m)
- -24.8%
- ATR (14d, % of price)
- 2.11%
Earnings reactions
How WST moved around its past quarterly results.
Next earnings release
Oct 29, 2026 · In 5 days · Before the open
EPS estimate: 2.20Revenue estimate: $827M
What usually happens
- Over the last 12 releases the stock moved a median of 11.9% the next day, up or down.
- Next-day moves: up 4, down 8 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | Before the open | 2.10 | 2.37 | +12.8% | +7.4% | -0.8% | -5.8% |
| Apr 23, 2026 | Before the open | 1.69 | 2.13 | +25.8% | +12.2% | +12.9% | +7.6% |
| Feb 12, 2026 | Before the open | 1.85 | 2.04 | +10.2% | +1.6% | -1.0% | -0.9% |
| Oct 23, 2025 | Before the open | 1.70 | 1.96 | +15.4% | +8.7% | +10.9% | +2.8% |
| Jul 24, 2025 | Before the open | n/a | n/a | n/a | +24.0% | +22.8% | +9.6% |
| Apr 24, 2025 | Before the open | n/a | n/a | n/a | 0.0% | -3.5% | -3.2% |
| Feb 13, 2025 | Before the open | n/a | n/a | n/a | -24.3% | -38.2% | -36.8% |
| Oct 24, 2024 | Before the open | n/a | n/a | n/a | +14.3% | +15.4% | +9.3% |
| Jul 25, 2024 | Before the open | n/a | n/a | n/a | -12.8% | -14.4% | -5.4% |
| Apr 25, 2024 | Before the open | n/a | n/a | n/a | -0.3% | -4.5% | -5.8% |
| Feb 15, 2024 | Before the open | n/a | n/a | n/a | -17.2% | -14.1% | -11.8% |
| Oct 26, 2023 | Before the open | n/a | n/a | n/a | -8.4% | -8.6% | -10.1% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on WST and what the price did next.
- 4/23/2026PositiveWest Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for WST.
- 4/23/2026POSITIVEWest Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
West Pharmaceutical Services Inc. reported Q1 results that surpassed analyst expectations, driven by robust demand for GLP-1 drug delivery components. The company has consequently raised its full-year 2026 financial guidance, signaling strong confidence in continued growth. Furthermore, West Pharmaceutical announced a new $1 billion share repurchase program, indicating a commitment to returning capital to shareholders. This combination of exceeding current performance, improving future outlook, and enhancing shareholder value makes the stock an attractive prospect for investors.